Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor‐Naïve Patients With Myelofibrosis From the Multicenter, Open‐Label, Phase 2 Study (REFINE)
Hematological Oncology · 2026
DOI: 10.1002/hon.70180 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Hematological Oncology, 2026. Verfasst von Francesco Passamonti und 16 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, It…. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Pyrazoles, Sulfonamides, Aniline Compounds. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Myelofibrosis is characterized by perturbation of the JAK/STAT pathway and upregulation of anti‐apoptotic factors leading to myeloproliferation, bone marrow fibrosis (BMF), extramedullary hematopoiesis, splenomegaly, and cytopenias. Navitoclax, a potent oral B‐cell lymphoma (BCL)‐X L /BCL‐2 inhibitor, promotes apoptosis of malignant myelofibrosis cells. Herein, we present results of Cohort 3 of the Phase 2 REFINE study (NCT03222609), which evaluated efficacy and safety of navitoclax plus ruxolitinib in JAKi‐naïve patients with myelofibrosis. JAKi‐naïve patients with primary or secondary myelofibrosis (≥ 18 years with splenomegaly, DIPSS intermediate‐2 and high‐risk myelofibrosis, and ECOG 0–2) and platelet count > 100 × 10 9 /L were enrolled and treated with navitoclax 100 mg once daily (QD) or 200 mg QD according to platelet count (≤ 150 × 10 9 /L or > 150 × 10 9 /L, respectively). Ruxolitinib was given twice daily (dose per label). Primary endpoint: spleen volume reduction of ≥ 35% (SVR 35 ) at week 24. Secondary endpoints: ≥ 50% reduction in total symptom score (TSS 50 ) at week 24, change in grade of BMF, anemia response, and safety. Thirty‐two patients received ≥ 1 dose of navitoclax plus ruxolitinib. Median (range) duration of follow‐up was 44 months (5–58). 63% (20/32) of patients achieved SVR 35 at week 24; median (range) time to first SVR 35 was 12 weeks (11─48). Of 24 evaluable patients, 21% achieved ≥ 50% reduction in driver gene variant allele frequency (VAF). Of 27 evaluable patients, 11 (41%) achieved TSS 50 at week 24; median (range) time to first TSS 50 of 3 weeks (0─16). BMF improved from baseline by ≥ 1 grade in 13/27 patients (48%) at any time on study. Anemia response rates were 38% (5/13) for transfusion‐independent and 100% (2/2) for transfusion‐dependent patients. No bleeding events or deaths were attributed to navitoclax. These findings suggest navitoclax plus ruxolitinib has a tolerable safety profile and provides clinically meaningful improvements for JAKi‐naïve patients with myelofibrosis. Trial Registration NCT03222609.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
- Mayo Clinic, Jacksonville, Florida, USA.
- Indiana Blood and Marrow Transplant, Indianapolis, Indiana, USA.
- Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Rome, Italy.
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
- Department of Hematology, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Campus, Barcelona, Spain.
ORCID-Profile: James M Foran, Mary Frances McMullin, Andrew C Perkins
Förderung
- AbbVie
Zitieren
APA
Passamonti, F., Foran, J. M., Tandra, A., De Stefano, V., Fox, M. L., Mattour, A., McMullin, M. F., Perkins, A. C., Rodriguez-Macías, G., Sibai, H. A., Polepally, A. R., Sun, Y., Chopra, A. S., Harb, J. G., Qin, Q., Potluri, J., & How, J. (2026). Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor‐Naïve Patients With Myelofibrosis From the Multicenter, Open‐Label, Phase 2 Study (REFINE). Hematological Oncology. https://doi.org/10.1002/hon.70180
Vancouver
Passamonti F, Foran JM, Tandra A, De Stefano V, Fox ML, Mattour A, et al. Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor‐Naïve Patients With Myelofibrosis From the Multicenter, Open‐Label, Phase 2 Study (REFINE). Hematological Oncology. 2026. doi:10.1002/hon.70180
BibTeX
@article{Passamonti2026,
author = {Passamonti, Francesco and Foran, James M and Tandra, Anand and De Stefano, Valerio and Fox, Maria Laura and Mattour, Ahmad and McMullin, Mary Frances and Perkins, Andrew C and Rodriguez-Macías, Gabriela and Sibai, Hassan A and Polepally, Akshanth R and Sun, Yan and Chopra, Avijeet S and Harb, Jason G and Qin, Qin and Potluri, Jalaja and How, Jonathan},
title = {Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor‐Naïve Patients With Myelofibrosis From the Multicenter, Open‐Label, Phase 2 Study (REFINE)},
journal = {Hematological Oncology},
year = {2026},
doi = {10.1002/hon.70180}
}
EUVIMED